NanoInk launches new automated protein NanoArray assay platform

The Nano BioDiscovery™ Division of NanoInk®, Inc. announced today the release of a new automated platform for the analysis of its protein NanoArray assays. NanoInk’s NanoArray Assay System™ enables detection, identification, and quantitation of clinically relevant, low abundance proteins from a wide variety of sample types for applications such as biomarker analysis, translational medicine, and toxicology.

NanoInk assays consume much smaller sample and reagent volumes than do traditional ELISA and bead-based assays, generating more proteomic data with less starting material and lowering assay costs for tests that are typically expensive to run. These benefits are fully explained in a state-of-the-art high definition video entitled, “NanoArray Assays: More Proteomic Data from Less Sample,” and is now available on NanoInk’s Web site. With the aid of 3D animation, scientist interviews, and HD videography, the NanoInk platform comes alive.

As the video demonstrates, NanoInk’s assays provide customers the choice of automated proteomic analysis or simple bench top testing using standard immunoassay protocols; both formats are fully detailed. The automated format combines a small sample size advantage with the additional benefit of high-throughput precision and speed. The latest NanoInk assay kits include all protocols, reagents, and SBS compliant consumables needed to conduct NanoArray studies on commercially available lab automation systems. Additionally, NanoInk array slides are compatible with 96 and 384-well sample microplates. Customers can automate nanoscale proteomic analysis in their own lab or outsource these projects to NanoInk’s expert contract service team.

The ability to generate high-throughput proteomic data from very small sample volumes is especially critical when working with rare and hard-to-collect samples like rodent serum, spinal fluid, tissue extracts, rodent urine, saliva, sweat, tears, and dried blood spots. Whether using the automated or manual assay format, NanoInk’s miniaturized immunoassay platform can extract multiplexed protein biomarker data from just 2 μl of sample.

According to Bruce Dudzik, Vice President of the Nano BioDiscovery Division, “Life science researchers who find it difficult to extract usable protein biomarker data from limited sample volumes will find that the NanoInk platform enables them to successfully analyze more samples, faster.” The NanoArray Assay System is a user friendly, affordable desktop unit that can quickly and costeffectively integrate into any proteomic lab. It can create highly reproducible protein arrays over millimeter areas with nanometer precision and then can fluorescently image these NanoArrays with 0.5 μm resolution. With these exquisitely precise array deposition and ultra-high resolution detection capabilities, the NanoInk platform can achieve sub-picogram sensitivities with 2 μl or less of sample. This is comparable to or better than the sensitivity of ELISA and bead-based assays that require 50 μl or more of sample.

NanoInk’s new video demonstrates how the company helps its customers address major proteomic challenges with automated and miniaturized multiplexed NanoArray assays. Please visit to view this exciting and informative video production or for more information please call NanoInk Nano BioDiscovery at (847)679-3432.

NanoInk, Inc. is an emerging growth technology company specializing in nanometer-scale manufacturing and applications development for the life science and semiconductor industries. Using Dip Pen Nanolithography® (DPN®), a patented and proprietary nanofabrication technology, scientists are enabled to rapidly and easily create nanoscale structures from a wide variety of materials. This low cost, easy to use and scalable technique brings sophisticated nanofabrication to the laboratory desktop. Located in the new Illinois Science + Technology Park, north of Chicago, NanoInk currently has over 140 patents and applications filed worldwide and has licensing agreements with Northwestern University, Stanford University, University of Strathclyde, University of Liverpool, California Institute of Technology and the University of Illinois at Urbana-Champaign. For more information on products and services offered by NanoInk, Inc., see



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Review highlights the role of retinol-binding protein-4 in non-alcoholic fatty liver disease